Drug intelligence / Profile preview

TB-840

Development stage: Phase 1
Lead developer: Therasid Bioscience
Modality: Small Molecules
Administration: Oral

Overview

TB-840 is a small molecule drug candidate developed by Therasid Bioscience. It acts as an agonist of Retinoid-related orphan receptor alpha (RORα) and is currently undergoing Phase 1 clinical trials for the treatment of Non-alcoholic steatohepatitis (NASH). The drug is administered orally.

Targets

RORA (Retinoic acid-related orphan receptor alpha)

Beyond the preview

Go deeper on TB-840.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-840.

Explore the full profile